Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma
Toshihiko Iuchi(Chiba Cancer Center), Toshihiko Iizasa(Chiba Cancer Center), Kazuo Hatano(Astellas Pharma (Japan)), Masato Shingyoji(Chiba Cancer Center), K. Kawasaki(Osaka University of Economics), Osamu Nagano(Fujita Health University), Meiji Itakura(Chiba Cancer Center), Tsukasa Sakaida(Chiba Cancer Center), Hajime Kageyama(Chiba Cancer Center), S. Yokoi(Chiba Cancer Center), Yuzo Hasegawa(Chiba Cancer Center)
Cited by 261
Related Papers
Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell
|Nature Communications|2012|382
Transcriptional activation of early‐response genes by hydrogen peroxide in a mouse osteoblastic cell line
|European Journal of Biochemistry|1991|291
Regulation by Chemokines of Circulating Dendritic Cell Precursors, and the Formation of Portal Tract–Associated Lymphoid Tissue, in a Granulomatous Liver Disease
|The Journal of Experimental Medicine|2000|198
Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations
|International Journal of Clinical Oncology|2014|167